Cortex Pharmaceuticals, Inc.
Cortex Pharmaceuticals Inc. (OTC BB: CORX.OB)
Cortex Pharmaceuticals is a neuroscience company focused on the discovery, development and commercialization of novel drug therapies for the treatment of neurological and psychiatric disorders. Cortex’s primary technology platform is a novel class of proprietary pharmaceuticals called AMPAKINE® compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases.
Cortex Announces $1.5 Million Private Placement
Cortex Pharmaceuticals, Inc. (OTCBB (CORX)) announced that it has completed a private placement of $1.5 million in principal amount of a convertible promissory note with a single institutional investor, Samyang Optics Co., Ltd. (“Samyang”) of Korea. The note accrues interest at the rate of 6% per annum and may be converted into Cortex’s common stock at Samyang’s option at any time after April 15, 2010 and if not converted may be subject to repayment at its maturity date on January 15, 2011.
New Treatments for Sleep Apnea Sufferers
Approximately one in ten women and one in four men exhibit signs of sleep-disordered breathing, an umbrella term for a set of conditions that includes sleep apnea. Sleep apnea, in turn, comes in multiple variants, the most common of which is known as obstructive sleep apnea. This condition is characterized by numerous interruptions of breathing, lasting 10 seconds or more, that occur while the individual is asleep.
Like Michael Jackson's Performances, Pain Killers Can Literally Leave Us Breathless
An injection of propofol (Diprivan) could have led to respiratory depression -- and subsequently cardiac arrest -- if Michael Jackson indeed used the powerful anesthetic to battle insomnia, emergency physicians say.
“Propofol is an agent that requires very close monitoring and is often limited only to use by anesthesiologists,” said Dr. John Greer, PhD, from the University of Alberta. “The main concern with this agent is the risk of respiratory depression, which, in turn, could cause cardiac arrest.”
Published Study Shows Novel Compounds May Help Protect Against Respiratory Depression
A paper that appears in the June 2009 issue of Anesthesiology details how AMPAKINE CX717, a Phase II compound created by Irvine, California-based neuroscience company Cortex Pharmaceuticals, demonstrated the rescue of fentanyl-induced respiratory depression and sleep apnea in rats.
Sleep Apnea Prevalent Among NFL Retirees
Two-time National Football League Defensive Player of the Year Reggie White, who played for the Philadelphia Eagles, Green Bay Packers, and Carolina Panthers, famously suffered from sleep apnea.
Cortex Pharmaceuticals, Inc. Helps Sleep Apnea Sufferers Breathe Easy
Novel Therapy Believed To Provide Protection From Drug-Induced Respiratory Depression
Novel Therapy Allows Those With Sleep Apnea To Breathe Easy
Anesthesia can stay in the body for up to twenty-four hours after it is administered. A patient will not return to their normal self until the anesthetic is completely eliminated from the body.
The American Association of Nurse Anesthetists advises patients to avoid the following activities until anesthesia completely wears off: driving a car, operating complex equipment, signing any legal documents, taking medications other than those prescribed by your physician, and drinking alcohol.
Cortex Pharmaceuticals, Inc. Animal Studies Demonstrate Reversal of Memory Loss In Huntington’s Disease
Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) recently reported that preclinical studies from the laboratory of Professor Gary Lynch at the University of California Irvine, one of the scientific founders of the company, demonstrated that AMPAKINE® molecules show promise in the treatment of memory loss in Huntington’s disease. The studies were performed in mice harboring the genetic mutation found in humans that is responsible for Huntington’s disease.
Cortex Pharmaceuticals, Inc. - NAPSTV - Health News
People having surgery may be better able to breathe easy these days. That's because doctors are discovering better ways to protect their patients' lives. The problem is that
